Trial
NCT03123393
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Calithera Biosciences, Inc
Collaborators
—
Condition
Diffuse Large B-cell Lymphoma
Intervention
TAK-659
Why stopped
Lack of efficacy of the drug; no safety concern
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-08